← Leaderboards
Sherry Chow
$2,645,090
Attributed
$2,645,090
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2015–19$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,645,090 · 1
By mechanism
N01$2,645,090 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Visit”
- Jeffrey P Krischer · University Of South Florida$268,700,989
- Michelle Vargas · Ppd Development Lp$176,419,297
- Kimberly Smith · Ppd Development Lp$115,671,664
- David Heimbrook · Leidos Biomedical Research, Inc.$98,650,141
- Jeffrey S Flier · Beth Israel Deaconess Medical Center$87,858,851
- Richard A Gibbs · Baylor College Of Medicine$82,807,896
Research focus
VisitClinical TrialsDoseEnrollmentFollow-UpGirlsHuman PapillomavirusHuman Papillomavirus 16Human Papilloma Virus VaccineImmune ResponseImmunogenicityOpen LabelProphylacticProspective12 Year OldSafetyScheduleSerologicalUnited StatesVaccinationVaccinesRandomized
Grant awards (3)
A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, PHASE IIA TRIAL OF A NONAVALENT PROPHYLACTIC HPV VACCINE TO ASSESS IMMUNOGENICITY OF A PRIME AND DEFERRED-BOOSTER DOSING SCHEDULE$139,720
N01 · FY2019 · CA · contact PI
IGF::OT::IGF - A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, PHASE IIA TRIAL OF A NONAVALENT PROPHYLACTIC HPV VACCINE TO ASSESS IMMUNOGENICITY OF A PRIME AND DEFERRED-BOOSTER DOSING SCHEDULE$1,345,730
N01 · FY2016 · CA · contact PI
IGF::OT::IGF - A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, PHASE IIA TRIAL OF A NONAVALENT PROPHYLACTIC HPV VACCINE TO ASSESS IMMUNOGENICITY OF A PRIME AND DEFERRED-BOOSTER DOSING SCHEDULE$1,159,640
N01 · FY2015 · CA · contact PI